Journal for ImmunoTherapy of Cancer: 12 (7)

Commentary

Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy (24 July, 2024)
Tomoko Akaike, Austin J Jabbour, Peter H Goff, Song Y Park, Shailender Bhatia, Paul Nghiem
Acknowledging and addressing real-world challenges to treating immune-related adverse events (22 July, 2024)
Mitchell S von Itzstein, David E Gerber, Bonnie L Bermas, Alexa Meara
A crisis in clinical research (11 July, 2024)
David S Hong, Patricia LoRusso, Mario Sznol

Basic tumor immunology

Original research: Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy (31 July, 2024)
Mingyi Ju, Jiaojiao Zhang, Zhuoyuan Deng, Minjie Wei, Lianghua Ma, Ting Chen, Lin Zhao
Original research:
POSTN⁺ cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma
(27 July, 2024)
Hao Wang, Yuan Liang, Zheng Liu, Rui Zhang, Jiashuo Chao, Mingming Wang, Mu Liu, Lei Qiao, Zhengfeng Xuan, Haitao Zhao, Ling Lu
Original research: Immune cell topography of head and neck cancer (24 July, 2024)
Tara Muijlwijk, Dennis N L M Nijenhuis, Sonja H Ganzevles, Fatima Ekhlas, Carmen Ballesteros-Merino, Laura A N Peferoen, Elisabeth Bloemena, Bernard A Fox, Jos B Poell, C René Leemans, Ruud H Brakenhoff, Rieneke van de Ven
Original research: Hypoxia inhibits the iMo/cDC2/CD8+ TRMs immune axis in the tumor microenvironment of human esophageal cancer (4 July, 2024)
Chuanqiang Wu, Huan Yu, Fuxiang Liang, Xiancong Huang, Bin Jiang, Zhiling Lou, Yafei Liu, Zixiang Wu, Qi Wang, Hong Shen, Ming Chen, Pin Wu, Ming Wu
Original research: IFNγ mediates the resistance of tumor cells to distinct NK cell subsets (1 July, 2024)
Tomáš Hofman, Siu Wang Ng, Irene Garcés-Lázaro, Florian Heigwer, Michael Boutros, Adelheid Cerwenka

Clinical/translational cancer immunotherapy

Original research: Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies (29 July, 2024)
Atish Mohanty, Michelle Afkhami, Amanda Reyes, Rebecca Pharaon, Holly Yin, Haiqing Li, Dana Do, Diana Bell, Arin Nam, Sue Chang, Thomas Gernon, Robert Kang, Arya Amini, Sagus Sampath, Prakash Kulkarni, Raju Pillai, Vicky Villaflor, Ravi Salgia, Ellie Maghami, Erminia Massarelli
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort (27 July, 2024)
Sandip P Patel, Megan Othus, Young Kwang Chae, Tridu Huynh, Benjamin Tan, Timothy Kuzel, Christine McLeod, Gabby Lopez, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles Blanke, Razelle Kurzrock
Original research: Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214 (25 July, 2024)
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albigès, Lisa Rosenblatt, Michael B Atkins, Meredith M Regan, David F McDermott
Original research: FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription (25 July, 2024)
Xuemei Li, Lei Gao, Bofang Wang, Jike Hu, Yang Yu, Baohong Gu, Lin Xiang, Xiaomei Li, Haiyuan Li, Tao Zhang, Yunpeng Wang, Chenhui Ma, Jiahong Dong, Jianrong Lu, Alexandra Lucas, Hao Chen
Original research: Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers (24 July, 2024)
Noboru Yamamoto, Shigehisa Kitano, Takafumi Koyama, Masafumi Ikeda, Hidenori Mizugaki, Takatsugu Narikiyo, Yuki Yamaguchi, Takaaki Ishida, Ryoko Takubo, Chika Ogami, Mayuko Sekiya, Yuki Nakagawa, Yasutoshi Kuboki
Original research: Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases (22 July, 2024)
Chandra C Ghosh, Lauren Cournoyer, Yujia Liu, Alizee Ballarin, Ilan B Layman, Jason LaPorte, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha, Prajna Guha, Steven C Katz, Diwakar Davar
Original research: Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer (22 July, 2024)
Niels E Wondergem, Iris H C Miedema, Rieneke van de Ven, Gerben J C Zwezerijnen, Pim de Graaf, K Hakki Karagozoglu, Jan-Jaap Hendrickx, Simone E J Eerenstein, Rolf J Bun, Dorien C Mulder, Jens Voortman, Ronald Boellaard, Albert D Windhorst, J Pascal Hagers, Laura A N Peferoen, Tanja D de Gruijl, Elisabeth Bloemena, Ruud H Brakenhoff, C René Leemans, C Willemien Menke-van der Houven van Oordt
Original research: Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors (20 July, 2024)
Patrick Tiongco Magahis, Tara Corso, Pamela Livingstone, Erika Tom, Amitabh Srivastava, Michael Postow, David Faleck
Original research: Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective – a SENTICOL ancillary study (15 July, 2024)
Gaurav Thareja, Anna Salvioni, Françoise Lauzeral-Vizcaino, Najeeb Halabi, Eliane Mery-Lamarche, Noemie Thebault, Clara-Maria Scarlata, Marie Michelas, Anne-Sophie Navarro, Gwenaël Ferron, Fabrice Lecuru, Patrice Mathevet, Jonathan Khalifa, Maha Ayyoub, Arash Rafii, Alejandra Martinez
Original research: Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment (15 July, 2024)
Yoonjeong Choi, Seong A Kim, Hanul Jung, Eunhae Kim, Yoon Kyoung Kim, Seohyun Kim, Jaehyun Kim, Yeji Lee, Min Kyoung Jo, Jiwan Woo, Yakdol Cho, Dongjoo Lee, Hongyoon Choi, Cherlhyun Jeong, Gi-Hoon Nam, Minsu Kwon, In-San Kim
Original research: Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species (14 July, 2024)
Man Zhu, Wenjun Tang, Xiaoyu Tang, Zeren Zhu, Yina Jiang, Ammar Sarwar, Hongmei Zhang, Dake Chu, Zixi Zhang, Yanmin Zhang
Original research: Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors (11 July, 2024)
Juan Chen, Jia-Si Liu, Jun-Yan Liu, Lei She, Ting Zou, Fan Yang, Xiang-Ping Li, Zhan Wang, Zhaoqian Liu
Original research: Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma (8 July, 2024)
Yang Chen, Yu Zhou, Ran Ren, Yu Chen, Juan Lei, Yongsheng Li
Original research: Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids (5 July, 2024)
Elias Burri, Joanna Mangana, Phil F Cheng, Alia Schneider, Achim Weber, Reinhard Dummer, Egle Ramelyte
Original research: Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations (4 July, 2024)
Jane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, Heather Jackson, Laura Seestaller-Wehr, David Kilian, Laura Bover, Kui S Voo, Kerry L Cox, Tom Murray, Mel John, Hong Shi, Paul Bojczuk, Junping Jing, Heather Niederer, Andrew J Shepherd, Laura Hook, Stephanie Hopley, Tatyana Inzhelevskaya, Chris A Penfold, C Ian Mockridge, Vikki English, Sara J Brett, Roopa Srinivasan, Christopher Hopson, James Smothers, Axel Hoos, Elaine Paul, Stephen L Martin, Peter J Morley, Niranjan Yanamandra, Mark S Cragg
Original research:
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8⁺ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers
(4 July, 2024)
Junsik Park, Jung Chul Kim, Yong Jae Lee, Sunghoon Kim, Sang Wun Kim, Eui-Cheol Shin, Jung Yun Lee, Su-Hyung Park
Original research: Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization (1 July, 2024)
William Becker, Purevdorj B Olkhanud, Noriko Seishima, Paloma A Moreno, Katherine C Goldfarbmuren, Hoyoung M Maeng, Jay A Berzofsky

Hypothesis

Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors? (20 July, 2024)
Manar Elsayed, Carrie Ye
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines (8 July, 2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley

Immune cell therapies and immune cell engineering

Original research: Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma (25 July, 2024)
Charlotte L B M Korst, Chloe O’Neill, Wassilis S C Bruins, Meliha Cosovic, Inoka Twickler, Christie P M Verkleij, Diane Le Clerre, Maria Themeli, Isabelle Chion-Sotinel, Sonja Zweegman, Roman Galetto, Tuna Mutis, Niels W C J van de Donk
Original research: Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy (25 July, 2024)
Haider Al-janabi, Katy Moyes, Richard Allen, Matthew Fisher, Mateus Crespo, Bora Gurel, Pasquale Rescigno, Johann de Bono, Harry Nunns, Christopher Bailey, Anna Junker-Jensen, Munitta Muthana, Wayne A Phillips, Helen B Pearson, Mary-Ellen Taplin, Janet E Brown, Claire E Lewis
Original research: Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells (24 July, 2024)
Anders W Matson, Rob Hullsiek, Kate J Dixon, Sam Wang, Anders J Lindstedt, Ryan R Friess, Shee Kwan Phung, Tanya S Freedman, Martin Felices, Emily N Truckenbrod, Jianming Wu, Jeffrey S Miller, Bruce Walcheck
Original research: rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors (23 July, 2024)
Dan Li, Tianyuzhou Liang, Laura E Hutchins, Alexandra A Wolfarth, Sara Ferrando-Martinez, Byung Ha Lee, Mitchell Ho
Original research: Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma (23 July, 2024)
Jessica A Lake, Elena Woods, Eric Hoffmeyer, Kristin L Schaller, Joselyn Cruz-Cruz, Joseph Fernandez, Dejene Tufa, Benjamin Kooiman, Spencer C Hall, Dallas Jones, Masanori Hayashi, Michael R Verneris
Original research: First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors (22 July, 2024)
Martin Wermke, Tobias A W Holderried, Jason John Luke, Van K Morris, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Ignacio I Wistuba, Edwin R Parra, Mohammad B Hossain, Sandra Grund-Gröschke, Katrin Aslan, Arun Satelli, Anantha Marisetty, Swapna Satam, Mamta Kalra, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Linus Backert, Melissa Baumeister, Sebastian Bunk, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Andrea Mayer-Mokler, Norbert Hilf, Delfi Krishna, Steffen Walter, Apostolia M Tsimberidou, Cedrik M Britten
Original research: Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy (20 July, 2024)
Helena Arellano-Ballestero, Agnieszka Zubiak, Chris Dally, Kim Orchard, Aljawharah Alrubayyi, Xenia Charalambous, Melina Michael, Robert Torrance, Trinity Eales, Kushal Das, Maxine G. B. Tran, May Sabry, Dimitra Peppa, Mark W. Lowdell
Original research: Generation of non-genetically modified, CAR-like, NK cells (18 July, 2024)
Loïs Coënon, Emilie Rigal, Hortense Courot, Caroline Multrier, Sara Zemiti, Jennifer Lambour, Martine Pugnière, Marion de Toledo, Guillaume Bossis, Guillaume Cartron, Bruno Robert, Pierre Martineau, Bénédicte Fauvel, Jessy Presumey, Martin Villalba
Original research: Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin (4 July, 2024)
Liuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Dinglan Wu, Jichao Sun, Chengchao Xu, Zhijie Li, Jigang Wang
Original research: Genetically engineering glycolysis in T cells increases their antitumor function (4 July, 2024)
Raphaëlle Toledano Zur, Orna Atar, Tilda Barliya, Shiran Hoogi, Ifat Abramovich, Eyal Gottlieb, Noga Ron-Harel, Cyrille J Cohen
Original research: Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model (1 July, 2024)
Inés Sánchez-Moreno, Aritz Lasarte-Cia, Celia Martín-Otal, Noelia Casares, Flor Navarro, Marta Gorraiz, Patricia Sarrión, Sandra Hervas-Stubbs, Lorea Jordana, Juan Roberto Rodriguez-Madoz, Jesús San Miguel, Felipe Prosper, Juan Jose Lasarte, Teresa Lozano
Original research: Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma (1 July, 2024)
Sushma Bharadwaj, Eric Lau, Mark P Hamilton, Anmol Goyal, Hrishi Srinagesh, Alexandria Jensen, Dasom Lee, Jayasindhu Mallampet, Sarah Elkordy, Shriya Syal, Sunita Patil, Theresa Latchford, Bita Sahaf, Sally Arai, Laura J Johnston, Robert Lowsky, Robert Negrin, Andrew R Rezvani, Judith Shizuru, Everett H Meyer, Parveen Shiraz, Lekha Mikkilineni, Wen-Kai Weng, Melody Smith, Surbhi Sidana, Lori Muffly, Holden T Maecker, Matthew J Frank, Crystal Mackall, David Miklos, Saurabh Dahiya

Immunotherapy biomarkers

Original research: Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and accelerates immunotherapy (31 July, 2024)
Motoki Nakamura, Tetsuya Magara, Maki Yoshimitsu, Shinji Kano, Hiroshi Kato, Keisuke Yokota, Katsuhiro Okuda, Akimichi Morita
Original research: Density of tertiary lymphoid structures predicts clinical outcome in breast cancer brain metastasis (27 July, 2024)
Yuan-Yuan Zhao, Zhen Fan, Bao-Rui Tao, Zun-Guo Du, Zhi-Feng Shi
Original research:
NAD⁺ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer
(27 July, 2024)
Meihua Yang, Bo Wang, Weibin Hou, Honghui Zeng, Wang He, Xin-Ke Zhang, Dong Yan, Hao Yu, Long Huang, Lu Pei, Kaiwen Li, Haide Qin, Tianxin Lin, Jian Huang
Original research:
ImmunoPET imaging of LAG-3 expression in tumor microenvironment with ⁶⁸Ga-labelled cyclic peptides tracers: from bench to bedside
(25 July, 2024)
Ming Zhou, Bei Chen, Chenxi Lu, Jinhui Yang, Peng Liu, Xiaobo Wang, Shuo Hu
Original research: Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma (23 July, 2024)
Peizhe Yuan, Yu Long, Nannan Wei, Yan Wang, Ziyang Zhu, Jinquan Han, Dawei Jiang, Xiaoli Lan, Yongkang Gai
Original research: Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma (23 July, 2024)
Takashi Yoshida, Takahiro Nakamoto, Naho Atsumi, Chisato Ohe, Takeshi Sano, Yoshiki Yasukochi, Koji Tsuta, Hidefumi Kinoshita
Original research: Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy (18 July, 2024)
Yonglin Hua, Zhixian Sun, Yuxin Xiao, Huilong Li, Xiaowu Ma, Xuan Luo, Wenliang Tan, Zhiqin Xie, Ziyu Zhang, Chenwei Tang, Hongkai Zhuang, Weikai Xu, Haihong Zhu, Yajin Chen, Changzhen Shang
Original research: TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response (5 July, 2024)
Saraí G De León-Rodríguez, Cristina Aguilar-Flores, Julián A Gajón, Ángel Juárez-Flores, Alejandra Mantilla, Raquel Gerson-Cwilich, José Fabián Martínez-Herrera, Diana Alejandra Villegas-Osorno, Claudia T Gutiérrez-Quiroz, Sergio Buenaventura-Cisneros, Mario Alberto Sánchez-Prieto, Edmundo Castelán-Maldonado, Samuel Rivera Rivera, Ezequiel M Fuentes-Pananá, Laura C Bonifaz
Original research: Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin–etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment (1 July, 2024)
Anna Tosi, Martina Lorenzi, Paola Del Bianco, Anna Roma, Alberto Pavan, Antonio Scapinello, Maria Vittoria Resi, Laura Bonanno, Stefano Frega, Fiorella Calabrese, Valentina Guarneri, Antonio Rosato, Giulia Pasello
Original research: Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer (1 July, 2024)
Juan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, Catherine Genestie, Etienne Rouleau, Marco de Bruyn, Christophe Klein, Audrey Le Formal, Elodie Edmond, Maëva Moreau, Annechien Plat, Sebastien Gouy, Amandine Maulard, Patricia Pautier, Judith Michels, Ana Oaknin, Emeline Colomba-Blameble, Alexandra Leary
Original research: Mapping the complexity and diversity of tertiary lymphoid structures in primary and peritoneal metastatic gastric cancer (1 July, 2024)
Tessa S Groen-van Schooten, Rosalia Franco Fernandez, Nicole C T van Grieken, Emma N Bos, Jens Seidel, Job Saris, Carolina Martínez-Ciarpaglini, Tania C Fleitas, Daniela S Thommen, Tanja D de Gruijl, Joep Grootjans, Sarah Derks

Oncolytic and local immunotherapy

Original research: TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment (25 July, 2024)
Fadi Azar, Jules Deforges, Christelle Demeusoit, Patricia Kleinpeter, Christelle Remy, Nathalie Silvestre, Johann Foloppe, Laetitia Fend, Clémentine Spring-Giusti, Eric Quéméneur, Jean-Baptiste Marchand
Original research: Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling (25 July, 2024)
Edward Armstrong, Matthew K L Chiu, Shane Foo, Lizzie Appleton, Pablo Nenclares, Anton Patrikeev, Nitya Mohan, Martin Mclaughlin, Galabina Bozhanova, Julia Hoebart, Victoria Roulstone, Emmanuel Patin, Malin Pedersen, Joan Kyula, Masahiro Ono, Fiona Errington-Mais, John Bell, Kevin J Harrington, Alan Melcher, Victoria Jennings

Review

Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee (20 July, 2024)
Anne Monette, Sarah Warren, J Carl Barrett, Charlie Garnett-Benson, Kurt A Schalper, Janis M Taube, Brian Topp, Alexandra Snyder
Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update (4 July, 2024)
Kylie Fletcher, Douglas B Johnson

Correction

Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3 (10 July, 2024)

Main menu

Table of contents

July 2024 - Volume 12 - 7

Commentary

Basic tumor immunology

Clinical/translational cancer immunotherapy

Hypothesis

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Oncolytic and local immunotherapy

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

July 2024 - Volume 12 - 7

Commentary

Basic tumor immunology

Clinical/translational cancer immunotherapy

Hypothesis

Immune cell therapies and immune cell engineering

Immunotherapy biomarkers

Oncolytic and local immunotherapy

Review

Correction